Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy
2020 · Biomedicine & Pharmacotherapy · 31 citations
https://doi.org/10.1016/j.biopha.2020.110457
K
Keyan Yang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
56
Papers
413
Citations
12
h-index
15
i10-index
Keyan Yang is an academic researcher from Fujian Normal University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lymphoma Diagnosis and Treatment & Acute Lymphoblastic Leukemia research. The author has an h-index of 12, co-authored 48 publications.
ORCID: 0000-0003-0936-7063Papers by this author
worksER Ca2+ overload activates the IRE1α signaling and promotes cell survival
2023 · Cell & Bioscience · 28 citations
https://doi.org/10.1186/s13578-023-01062-y
Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy
2023 · Cancer Cell International · 4 citations
https://doi.org/10.1186/s12935-023-03122-2
CD7 CART Therapy Bridging Allo-HSCT Remarkably Improves Long-Term DFS in Refractory/Relapsed T-ALL/LBL
2024 · Transplantation and Cellular Therapy · 3 citations
https://doi.org/10.1016/j.jtct.2024.11.009
Additional file 1 of Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.16928613
MOLECULAR PROFILING AND ITS PROGNOSTIC IMPACT OF CHINESE PEDIATRIC PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA
2025 · Leukemia Research · 0 citations
https://doi.org/10.1016/j.leukres.2025.107985
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat